Collaboration

PD-L1 virtual training course – Test Agnostic Professional Expert Course for European labs

United Kingdom   Training

Details

PD-L1 precision medicine has rapidly expanded in the last few years however, with a range of PD-L1/PD-1 precision medicine therapies existing alongside several commercially available assays and standalone antibodies. As a result, recommendations regarding scoring algorithms and clinical cut-offs can vary depending on the assay-indication combination and may result in the incorrect test being performed and the patient receiving a result that is incorrectly matched to the therapy being considered.

Diaceutics has partnered with internationally established healthcare service partner Targos to bring you this opportunity to receive PD-L1 agnostic training.

There are two virtual training courses, organised by timezone (GMT or CEST), and both taking place on the 19th and 20th of October for a duration of 4 hours each day. Further information on the agenda and schedule is contained within the accompanying documents accessible at the bottom of this page.
Note: Participation for this Collaboration is strictly limited to 20 applicants, and applications will close once this number is reached.

Why join the collaboration:

· Receive Diaceutics sponsorship to participate in a virtual training program that will help you develop knowledge of the scoring of PD-L1 (TPS/CPS/IC) in HNSCC, UC, GC and TNBC

· Gain a deeper understanding regarding the complexities associated with quality assurance (internal and external) as well as implementation and validation of PD-L1 testing in the laboratory

· Participate in an interactive digital microscope session that reviews example cases for each indication and scoring algorithms

· Use an online platform (PathXL) to perform self-assessment with example images

Requirements

To benefit from this opportunity, please ensure that lab assay details in “Assay Management” section reflects the following information for Q1 2021 & Q2 2021:

· NSCLC disease volume and corresponding PD-L1 biomarker volume and testing method(s)/assay(s)

· Triple Negative Breast Cancer disease volume and corresponding PD-L1 biomarker volume and testing method(s)/assays(s)

· H&N Cancer disease volume and corresponding PD-L1 biomarker volume and testing method(s)/assay(s)

· Urothelial Cancer disease volume and corresponding PD-L1 biomarker volume and testing method(s)/assay(s)

· Gastric Cancer disease volume and corresponding PD-L1 biomarker volume and testing method(s)/assay(s)

The information above will help Diaceutics understand how testing is performed in your lab and will enable us to design strategies to support testing and patient treatment.


If your lab does not fulfil all the requirements but you are still interested in this collaboration, please send us a message via “Ask a question”.

Downloads

Downloads available for registered users. Sign up

TrainingAgenda GMT(UK)

(PDF document)

TrainingAgenda CEST(EU)

(PDF document)

Join this collaboration

Type: Training
Provider: Diaceutics

About the provider

Diaceutics
United Kingdom
Discover and create collaborations on DXRX Marketplace
Work end-to-end on any aspect of diagnostic development and commercialization, either by joining sponsored collaborations or creating your own on the marketplace.